In addition, in vivo experiments have confirmed that deletion of SLC7A11 gene has no effect on the anti-tumor response of T cells, but knockout of SLC7A11 gene in tumor cells can improve the efficacy of immunotherapy (83), which may be related to the decreased antioxidant activity of tumor cells and the increased cystine level in the microenvironment. The gene discussed is SLC7A11; the disease is neoplasm.